Cyclerion Therapeutics (NASDAQ:KRSA – Get Free Report) was upgraded by equities researchers at UBS Group to a “strong-buy” rating in a note issued to investors on Thursday, Zacks reports.
Separately, Zacks Research upgraded shares of Cyclerion Therapeutics to a “hold” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Cyclerion Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $55.00.
Get Our Latest Stock Analysis on Cyclerion Therapeutics
Cyclerion Therapeutics Stock Performance
Cyclerion Therapeutics Company Profile
Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases of the central nervous system. The company has concentrated on therapies designed to influence the nitric oxide–soluble guanylate cyclase signaling pathway, which may play a role in neurological and other debilitating conditions.
Cyclerion’s lead development program was IW-6463, an oral, central nervous system-penetrant soluble guanylate cyclase stimulator investigated for potential use in neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis.
Featured Articles
- Five stocks we like better than Cyclerion Therapeutics
- MarketBeat Week in Review – 09/07 – 09/11
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
